{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:14:06Z","timestamp":1783350846355,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1053\/j.ajkd.2007.03.009","type":"journal-article","created":{"date-parts":[[2007,5,30]],"date-time":"2007-05-30T14:42:18Z","timestamp":1180536138000},"page":"801-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Parathyroidectomy Versus Cinacalcet Hydrochloride\u2013Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis"],"prefix":"10.1053","volume":"49","author":[{"given":"Rajeev","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Berbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Sawyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred E.","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle M.","family":"Vidal-Trecan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2007.03.009_bib1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1081\/JDI-120022551","article-title":"Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race","volume":"25","author":"Owda","year":"2003","journal-title":"Ren Fail"},{"issue":"suppl 5","key":"10.1053\/j.ajkd.2007.03.009_bib2","doi-asserted-by":"crossref","first-page":"SV15","DOI":"10.1093\/ndt\/gfh1051","article-title":"The need for better control of secondary hyperparathyroidism","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.03.009_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ndt\/gfi213","article-title":"Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: A cross-sectional multicentre study","volume":"21","author":"Lorenzo","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.03.009_bib4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: Review of the disease and its treatment","volume":"26","author":"de Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"10.1053\/j.ajkd.2007.03.009_bib5","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","article-title":"Survival following parathyroidectomy among United States dialysis patients","volume":"66","author":"Kestenbaum","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib6","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib7","series-title":"Wholesale Drug Prices","year":"2006"},{"key":"10.1053\/j.ajkd.2007.03.009_bib8","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.03.009_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.03.009_bib10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.03.009_bib11","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.clinthera.2005.11.015","article-title":"Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism","volume":"27","author":"Dong","year":"2005","journal-title":"Clin Ther"},{"key":"10.1053\/j.ajkd.2007.03.009_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0272989X9701700202","article-title":"Primer on medical decision analysis: Part 2\u2014Building a tree","volume":"17","author":"Detsky","year":"1997","journal-title":"Med Decis Making"},{"key":"10.1053\/j.ajkd.2007.03.009_bib13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1530\/eje.1.02029","article-title":"Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: A decision analysis","volume":"153","author":"Sejean","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.ajkd.2007.03.009_bib14","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/ndt\/17.12.2196","article-title":"Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias","volume":"17","author":"Mokrzycki","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.03.009_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/ajkd.2001.25199","article-title":"Hepatitis C screening strategies in hemodialysis patients","volume":"38","author":"Saab","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.03.009_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.03.009_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.surg.2005.08.036","article-title":"Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?","volume":"139","author":"Richards","year":"2006","journal-title":"Surgery"},{"key":"10.1053\/j.ajkd.2007.03.009_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib19","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.03.009_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.03.009_bib22","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.03.009_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00423-002-0322-x","article-title":"Operative treatment of renal autonomous hyperparathyroidism: Cause of persistent or recurrent disease in 304 patients","volume":"387","author":"Dotzenrath","year":"2003","journal-title":"Langenbecks Arch Surg"},{"key":"10.1053\/j.ajkd.2007.03.009_bib24","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1523-1755.2004.00590.x","article-title":"Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)","volume":"65","author":"Qunibi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib25","series-title":"Centers for Medicare & Medicaid Services: Average National Reimbursement Figures","year":"2005"},{"key":"10.1053\/j.ajkd.2007.03.009_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.otc.2004.02.016","article-title":"The cost-effectiveness of sestamibi scanning compared to bilateral neck exploration for the treatment of primary hyperparathyroidism","volume":"37","author":"Ruda","year":"2004","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1053\/j.ajkd.2007.03.009_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/000313480106700403","article-title":"Refractory renal hyperparathyroidism: Clinical features and outcome of surgical therapy","volume":"67","author":"McHenry","year":"2001","journal-title":"Am Surg"},{"key":"10.1053\/j.ajkd.2007.03.009_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00007890-200010150-00026","article-title":"Standards for economic and quality of life studies in transplantation","volume":"70","author":"Whiting","year":"2000","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2007.03.009_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"10.1053\/j.ajkd.2007.03.009_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1046\/j.1523-1755.2003.00157.x","article-title":"The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis","volume":"64","author":"McFarlane","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1542\/peds.106.4.756","article-title":"Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease","volume":"106","author":"Furth","year":"2000","journal-title":"Pediatrics"},{"key":"10.1053\/j.ajkd.2007.03.009_bib32","first-page":"40","article-title":"Body mass index and enrollment on the renal transplant waiting list in the United States","volume":"16","author":"Abbott","year":"2003","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2007.03.009_bib33","series-title":"USRDS 2005 Annual Data Report","article-title":"US Renal Data System","year":"2005"},{"key":"10.1053\/j.ajkd.2007.03.009_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","article-title":"A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States","volume":"66","author":"Manns","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.03.009_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.ki.5002037","article-title":"Cost of applying the K\/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients","volume":"71","author":"White","year":"2007","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607006440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607006440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:47:27Z","timestamp":1759456047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638607006440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0272638607006440"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.03.009","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parathyroidectomy Versus Cinacalcet Hydrochloride\u2013Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}